Linezolid induced thrombocytopenia in critically ill patients: Risk factors and development of a machine learning-based prediction model
- 14 May 2022
- journal article
- research article
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 28 (9) , 1249-1254
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patientsJournal of Antimicrobial Chemotherapy, 2012
- The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolidCurrent Medical Research and Opinion, 2010
- Thrombocytopenia and outcome in critically ill patients with bloodstream infectionHeart & Lung, 2010
- Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and managementJournal of Thrombosis and Haemostasis, 2009
- High frequency of linezolid-associated thrombocytopenia among patients with renal insufficiencyInternational Journal of Antimicrobial Agents, 2006
- Linezolid: low pre-treatment platelet values could increase the risk of thrombocytopeniaJournal of Antimicrobial Chemotherapy, 2005
- Risk factors for anaemia in patients on prolonged linezolid therapy for chronic osteomyelitis: a case–control studyJournal of Antimicrobial Chemotherapy, 2004
- Linezolid for the Treatment of Multidrug‐Resistant, Gram‐Positive Infections: Experience from a Compassionate‐Use ProgramClinical Infectious Diseases, 2003
- Intrapulmonary Pharmacokinetics of LinezolidAntimicrobial Agents and Chemotherapy, 2002
- Thrombocytopenia Associated with Linezolid TherapyClinical Infectious Diseases, 2002